Hims & Hers Health Inc SEC Filings

Hims & Hers Health, Inc. announced that its board has authorized a new share repurchase program allowing the company to buy back up to $250.0 million of its Class A common stock. The 2025 Share Repurchase Program runs through November 11, 2028 and allows purchases from time to time through open market transactions, privately negotiated deals, Rule 10b5-1 plans or other methods, and it may be suspended or discontinued at any time. The company also reported that from October 1, 2025 through November 7, 2025 it repurchased 1,334,572 shares for a total of $55.5 million, fully using the capacity of its prior $100.0 million repurchase program that began in July 2024.

Hims & Hers Health (HIMS) reported an insider stock sale by its Chief Legal Officer. On 11/10/2025, the officer sold 2,637 shares of Class A common stock at $42.53 per share pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024.

Following the sale, the officer beneficially owns 155,856 shares, held directly. This filing reflects a pre‑scheduled transaction under the company’s insider trading compliance framework.

Hims & Hers Health (HIMS) CEO Andrew Dudum reported multiple insider movements of Class A shares among family trusts, with no cash consideration, for estate-planning purposes.

Key actions include gifts and trust-to-trust transfers: 262,423 shares were gifted on 11/07/2025 from AD 2021 GRAT 2 to the Dudum Legacy 2021 Trust; 1,049,692 shares moved on 11/10/2025 from AD 2021 GRAT to the Dudum Family 2021 Trust; and 1,954,379 shares were gifted on 11/12/2025 from AD 2023 GRAT to the Dudum Family 2021 Trust. The Dudum Legacy 2021 Trust also made a pro rata distribution of 260,000 shares.

Dudum reports indirect holdings across multiple vehicles (GRATs and family trusts). The filing also lists Class V Common Stock, convertible into an equal number of Class A shares upon certain events, with 8,377,623 underlying Class A shares held by the Andrew Dudum 2015 Trust.

Hims & Hers Health (HIMS) received a Form 144 notice for a planned sale of 2,637 Class A shares. The filing lists an aggregate market value of $112,151.61, an approximate sale date of 11/10/2025, and execution on the NYSE through Fidelity Brokerage Services LLC.

The seller, Soleil Boughton, acquired these shares via restricted stock vesting on 09/15/2025 as compensation. Shares outstanding were 219,270,891. In the prior three months, the filing shows multiple sales by the same person, including 2,572 shares on 08/11/2025 for $132,818.08 and 2,571 shares on 08/25/2025 for $114,486.63.

Hims & Hers Health reported strong growth for Q3 2025. Revenue reached $598.976 million, up from $401.556 million a year ago, with gross profit of $442.058 million. For the nine months, revenue was $1.729 billion versus $995.375 million, and net income totaled $107.764 million compared with $100.013 million.

Quarterly net income was $15.774 million, reflecting higher operating expenses and a $7.626 million change in fair value of liabilities, partly offset by $8.042 million of other income and a $3.551 million tax benefit. Deferred revenue rose to $118.458 million from $75.285 million as more customers adopted prepaid offerings.

The balance sheet expanded following strategic moves. The company issued 2030 convertible notes, with convertible senior notes, net, at $971.023 million, and ended with $345.778 million in cash and cash equivalents and $722.306 million in investments. Total assets increased to $2.233 billion, including $259.236 million of goodwill and $194.931 million of intangible assets. Hims & Hers acquired Zava Global GmbH for EUR 219.2 million to expand in the U.K. and EU and invested in manufacturing and fulfillment capacity.

Hims & Hers Health, Inc. furnished a press release and a shareholder letter announcing results for the quarter ended September 30, 2025. The materials are provided as Exhibits 99.1 and 99.2. The information is furnished under Item 2.02 and is not deemed “filed” under the Exchange Act, nor incorporated by reference unless specifically stated. The company’s Class A common stock trades on the NYSE under the symbol HIMS.

Hims & Hers Health (HIMS): JPMorgan Chase & Co. filed a Schedule 13G reporting a passive stake in the company. The firm beneficially owns 17,796,759 Class A shares, representing 8.1% of the class as of 09/30/2025.

JPMorgan reports sole voting power over 16,040,252 shares and shared voting power over 110 shares. It has sole dispositive power over 17,760,085 shares and shared dispositive power over 14,016 shares. The filing certifies the shares were acquired and are held in the ordinary course of business and not to change or influence control.

Hims & Hers Health (HIMS) insider filing: Chief Legal Officer Soleil Boughton reported a sale of Class A Common Stock on 10/27/2025. The Form 4 lists a sale of 2,637 shares at a price of $50.10 per share, coded “S.” Following the transaction, the reporting person beneficially owns 158,493 shares, held directly.

The filing notes the trades were effected under a Rule 10b5-1 trading plan adopted on August 28, 2024. This disclosure reflects personal share transactions by an officer and does not describe company operating results.

Hims & Hers Health (HIMS) filed a Form 144 notice for the proposed sale of up to 2,637 shares of its Class A common stock. The filing lists an aggregate market value of $132,113.70, an approximate sale date of 10/27/2025, execution through Fidelity Brokerage Services LLC, and the listing on the NYSE.

The shares were acquired on 09/15/2025 via restricted stock vesting as compensation, in the same amount of 2,637 shares. Recent activity by the same seller shows additional open-market transactions in the past three months, including 2,572 shares on 07/28/2025 for $150,976.40 and 2,637 shares on 09/29/2025 for $155,029.23.